Prediction of the relationship between the structural features of andrographolide derivatives and αî±-glucosidase inhibitory activity: A quantitative structure-activity relationship (QSAR) Study

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 1, 2011, Pages 78-87

  Narayana Moorthy, N S Hari ^a   Ramos, Maria J ^a   Fernandes, Pedro A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

glucosidase inhibitory activity; andrographolide; petitjean; QSAR; volsurf

Indexed keywords

ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; ANDROGRAPHOLIDE; ANDROGRAPHOLIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; ELECTROPHILICITY; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ALPHA-GLUCOSIDASES; ANTIVIRAL AGENTS; BINDING SITES; DITERPENES; ENZYME INHIBITORS; HYDROGEN; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79851474038     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756361003724760     Document Type: Article

References (46)

1. Pili R, Chang J, Partis RA, Mueller RA, Chrest FJ, Passaniti A. Te α-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res 1995;55:2920-2926.
2. Humphries MJ, Matsumoto K, White SL, Olden K. Inhibition of experimental metastasis by castanospermine in mice: Blockage of two distinct stages of tumor colonization by oligosaccharide processing inhibitors. Cancer Res 1986;46:5215-5222. (Pubitemid 16008292)
3. Papandreou MJ, Barbouche R, Guieu R, Kieny MP, Fenouillet E. Te α-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodefciency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step. Mol Pharmacol 2002;61:186-193. (Pubitemid 34049526)
4. Ouzounov S, Mehta A, Dwek RA, Block TM, Jordan R. Te combination of interferon α-2b and n-butyl deoxynojirimycin has a greater than additive antiviral efect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: Implications for hepatitis C virus (HCV) therapy. Antiviral Res 2002;55:425-435. (Pubitemid 35223098)
5. Kameda Y, Asano N, Yoshikawa M. Valiolamine, a new α-glucosidase inhibiting aminocyclitol produced by Streptomyces hygroscopicus. J Antibiotics 1984;37:1301-1307. (Pubitemid 15220687)
6. Robinson KM, Begovic ME, Rhinehart BL, Heineke EW, Ducep JB, Kastner PR, Marshall FN, Danzin C. New potent α-glucohydrolase inhibitor MDL 73945 with long duration of action in rats. Diabetes 1991;40:825-830.
7. Fujisawa T, Ikegami H, Inoue K, Kawabata Y, Ogihara T. Efect of two α-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. Metab Clinic Exp 2005;54:387-390. (Pubitemid 40250100)
8. Van Den Broek LAGM, Kat-Van Den Nieuwenhof MWP, Butters TD, Van Boeckel CAA. Synthesis of α-glucosidase I inhibitors showing antiviral (HIV-1) and immunosuppressive activity. J Pharm Pharmacol 1996;48:172-178. (Pubitemid 26129086)
9. Gui FD, Hai WX, Jun FW, Feng WL, Hong ML. Studies on the novel α-glucosidase inhibitory activity and structure-activity relationships for andrographolide analogues. Bioorg Med Chem Lett 2006;16:2710-2713.
10. Silva CHTP, Taft CA. Computer aided molecular design of novel glucosidase inhibitors for AIDS treatment. J Biomol Struct Dyn 2004;22:59-63. (Pubitemid 39095283)
11. Fischer PB, Colin M, Karlson GB, James W, Butters TD, Davis SJ, Gordon S, Dwek RA, Platt FM. Te α-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodefciency virus entry at the level of post-CD4 binding. J Virol 1995;69:5791-5797.
12. Taylor DL, Kang MS, Brennan TM, Bridges CG, Sunkara PS, Tyms AS. Inhibition of α-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl Castanospermine (MDL 28,574) and its consequences in human immunodefciency virus infected T cells. Antimicrob Agents Chemother 1994;38:1780-1787. (Pubitemid 24250724)
13. Jung-Hum P, Sungmin K, Hwangseo P. Toward the virtual screening of α-glucosidase inhibitors with the homology-modelled protein structure. Bull Korean Chem Soc 2008;29:921-927.
14. Hwangseo P, Kyo YH, Young HK, Kyung HO, Jae YL, Keun K. Discovery and biological evaluation of novel α-glucosidase inhibitors with in vivo antidiabetic efect. Bioorg Med Chem Lett 2008;18:3711-3715
15. Rawling AJ, Lomas H, Adam WP, Marvin JRL, Dominic SA, Shane JSR, Sarah FJ, George WJF, Raymond AD, John HJ, Terry DB. Synthesis and biological characterization of novel N-alkyl deoxynojirimycin α-glucosidase inhibitors. ChemBioChem 2009;10:1101-1105.
16. Kavitha B, Nagakumar B, Ki HP, Keun WL. Binding mode analyses and pharmacophore model development for sulphonamide chalcone derivatives, a new class of α-glucosidase inhibitors. J Mol Graph Model 2008;26:1202-1212.
17. Tomich CH, da Silva P, Ivone C, Taft CA. Homology modelling and molecular interaction feld studies of α-glucosidase as a guide to structure based drug design of novel proposed anti-HIV inhibitors. J Comput Aided Drug Des 2005;19:83-92. (Pubitemid 40974009)
18. Karthikeyan C, Moorthy NSHN, Trivedi P. QSAR study of substituted 2-pyridinyl quanidine as selective urokinase-type plasminogen activator (uPA) inhibitors. J Enz Inhib Med Chem 2009;24:6-13.
19. Xu HW, Dai GF, Liu GZ, Wang JF, Liu HM. Synthesis of andrographolide derivatives: A new family of α-glucosidase inhibitors. Bioorg Med Chem 2007;15:4247-4255.
20. Prasanna S, Manivannan E, Chaturvedi SC. Quantitative structure-activity relationship analysis of a series of 2,3-diaryl benzopyran analogues as novel selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 2004;14:4005-4011. (Pubitemid 38844414)
21. Chem BioOfce 2008, CambridgeSoft, Cambridge UK. 2008.
22. MOE is a molecular modelling package developed by Chemical Computing Group, Montreal Canada. 2002
23. Systatica 8.0 statistical software, StatSoft, Tulsa, OK, USA. 2002.
24. Balaji S, Karthikeyan C, Moorthy NSHN, Trivedi P. QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P-VSA and pharmacophore feature descriptors. Bioorg Med Chem Lett 2004;14:6089-6094. (Pubitemid 39531278)
25. Cho DH, Lee SK, Kim BT, No KT. Quantitative Structure Activity relationship (QSAR) study of new fuorovinyloxyacetamides. Bull Korean Chem Soc 2001;22:388-394. (Pubitemid 32436156)
26. Durbin J, Watson GS. Testing for serial correlation in least squares regression. II. Biometrika 1951;38:159-178.
27. Tropsha A, Gramatica P, Gombar VK. Te importance of earnest, validation is the absolute essential application and interpretation of QSPR models. QSAR Comb Sci 2003;22:69-77. (Pubitemid 36717473)
28. Erikkson L, Jaworsha J, Worth AP, Mark TDC, Robert MM, Gramatica P. Methods for reliability and uncertainty assessment and for applicability evaluation of classifcation and regression based QSARs. Environ Health Perspect 2003;111:1361-1375. (Pubitemid 37021142)
29. Alexander G, Alexander T. Beware of Q2. J Mol Graphs Model 2002;20:269-276.
30. Gramatica P. Principle of QSAR Model validation: internal and external. QSAR Comb Sci 2007;26:694-701. (Pubitemid 46932857)
31. Cook RD. Infuential observation in linear regression. J Am Stat Assoc 1979;74:169-174.
32. Rotriquez G. Chapter 2, Linear models for continuous data, 1993-2000: 49-58 (Lecture Notes http://data.princeton.edu/wws509/notes)
33. Dogra, Shailay K. Script for computing linear regression diagnostics from QSAR world-free online resources for QSAR modelling. (http://www.qsarworld.com/ virtual-workshop.php.)
34. Wildman AS, Crippen GM. Prediction of physicochemical parameters by atomic contributions. J Chem Inf Comput Sci 1999;39:868-873.
35. Cruciania G, Crivorib P, Carruptb P-A, Testa B. Molecular felds in quantitative structure-permeation relationships: Te VolSurf approach. J Mol Struct (Teochem) 2000;503:17-30.
36. http://www.moldiscovery.com/docs/volsurf/descriptors.html#AEN669
37. Cruciani G, Pastor M, Guba W. Volsurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 2000;11:S29-S39.
38. Shahapurkar S, Kawathekar N, Chaturvedi SC. Quantitative structure activity relationship studies of diaryl thiophen derivatives as selective COX-2 inhibitors. Pharmazie 2005;60:254-258. (Pubitemid 40571186)
39. Petitjean M. Applications of the radius-diameter diagram to the classifcation of topological and geometrical shapes of chemical compounds. J Chem Inf Comput Sci 1992;32:331-337.
40. Petitjean M, Dubois JE. Topological statistics on a large structural fle. J Chem Inf Comput Sci 1990;30:332-343.
41. Iglika L, Andrew PW, Tatiana IN, John CD, Mark TDC Quantitative structure-activity-activity and quantitative structure-activity investigations of human and rodent toxicity. Chemosphere 2006;65:1878-1887.
42. Balasubramanian N, Avinash D, Vishnukant M. QSAR studies of 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines as potent angiotensin II receptor antagonists by MLR and NLR analysis. ARKIVOC 2007;i:189-1204.
43. Erol E, Hasan T, Semra G, Selami P, Oral O. A DFT-based QSARs study of acetazolamide/sulfanilamide derivatives with carbonic anhydrase (CA-II) isozyme inhibitory activity. Int J Mol Sci 2007;8:145-155.
44. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity\a rapid access to atomic charges. Tetrahedron 1980;36:3219-3228.
45. Mulliken RS. A new electroafnity scale; Together with data on valence states and on valence ionization potentials and electron afnities. J Chem Phys 1934;2:782-793.
46. Gnanadesikan R, Kettenring JR. Robust estimate, residuals and outlier detection with multipurpose data. Biometrics 1972;28:81-124.